NeuroSense Therapeutics Ltd. Logo

NeuroSense Therapeutics Ltd.

A late-clinical stage company developing drugs for neurodegenerative diseases like ALS.

NRSN | US

Overview

Corporate Details

ISIN(s):
IL0011809592 (+1 more)
LEI:
Country:
United States of America
Address:
11 HAMENOFIM ST., 4672562 HERZLIYA

Description

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NeuroSense Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NeuroSense Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NeuroSense Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ELUTIA INC. Logo
Develops drug-eluting biomaterials for medical implants and tissue reconstruction.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and delivers medical countermeasures for public health threats and crises.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Biotechnology company developing small molecule drugs for virology and immunology.
United States of America
ENTA
Enervit Logo
Develops sports nutrition, functional foods, and wellness supplements.
Italy
ENV
enGene Holdings Inc. Logo
Clinical-stage biotech developing non-viral gene therapies for local delivery.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
Clinical-stage biopharma developing kinase inhibitors for precision oncology.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
A clinical-stage macrophage reprogramming immunotherapy company.
Israel
ENLV
Enlivex Therapeutics Ltd. Logo
Develops macrophage reprogramming immunotherapy for inflammatory diseases.
United States of America
ENLV
Enorama Pharma AB Logo
Develops and manufactures medicated chewing gums and tobacco-free nicotine pouches.
Sweden
ERMA
Ensol Biosciences Inc. Logo
AI-driven biopharma developing peptide drugs for unmet medical needs.
South Korea
140610

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.